Extracts from a specially engineered chewing gum reduced HPV levels by up to 93% and, in an enhanced version, nearly eliminated two bacterial species associated with head and neck cancer in laboratory tests on patient samples, researchers at the University of Pennsylvania School of Dental Medicine reported. The experimental gum, made from lablab beans, contains a naturally occurring antiviral protein called FRIL and can be engineered to include an antimicrobial peptide that attacks harmful microorganisms while leaving the beneficial bacterial populations examined by researchers unaffected.
The research, led by Henry Daniell and reported in Scientific Reports, builds on earlier work developing a chewing gum from lablab beans that carries the FRIL protein. In tests, extracts from the gum lowered HPV levels by 93% in saliva samples and by 80% in oral rinse samples. A single dose of extract from an enhanced version containing the antimicrobial peptide protegrin reduced Porphyromonas gingivalis and Fusobacterium nucleatum, two bacteria associated with oral disease and poorer outcomes in some cancer patients, to almost undetectable levels.
Head and neck squamous cell carcinoma is a common cancer of the mouth and throat that can be difficult to treat once it spreads. Daniell noted that recently approved cancer medications have generally failed to produce major improvements in patients' quality of life or their chances of surviving five years after diagnosis, highlighting the need for new approaches. The study focused on microorganisms associated with these cancers, including HPV, which is linked to a global increase in oropharyngeal cancer, and the two bacterial species whose infections Daniell said worsen survival rates in untreated recurrent or metastatic oral cancer.
One of the most promising findings was the engineered gum extract's ability to sharply reduce the targeted bacteria without affecting the beneficial bacterial populations examined. The researchers say this selectivity could be especially valuable for patients whose oral health has already been affected by cancer or its treatment. However, the results come from laboratory testing of patient samples, not from human trials. Daniell believes the findings justify advancing toward clinical trials, potentially as an adjuvant to current treatments or as a prophylactic measure. “Our findings support the value of advancing these therapies to clinical trials as adjuvants with current treatments or as prophylaxis to prevent infection and transmission,” he said.
Analysis
Why This Matters
- The chewing gum approach could offer a simple, low-cost way to reduce cancer-linked microbes in the mouth, potentially improving outcomes for head and neck cancer patients.
- The ability to selectively target harmful bacteria without disturbing beneficial oral microbes addresses a common side effect of cancer treatments like radiation.
- The high reduction rates in HPV, a virus driving the global increase in oropharyngeal cancers, suggest the technology could serve as both a treatment support and a preventive measure.
Background
Head and neck squamous cell carcinoma (HNSCC) is a common cancer affecting the mouth and throat that often has poor survival outcomes, especially when metastasized. Certain oral microbes, including human papillomavirus (HPV) and bacteria such as Porphyromonas gingivalis and Fusobacterium nucleatum, have been linked to the development or progression of these cancers. The University of Pennsylvania team had previously developed a chewing gum from lablab beans containing the antiviral protein FRIL; the new study tested its effects on patient samples and engineered an enhanced version.
What to Watch
- Whether human clinical trials confirm the gum's effectiveness in reducing virus and bacterial levels in the mouth.
- How the engineered gum's selectivity for harmful microbes translates in real-world conditions, especially in patients undergoing cancer treatment.
- The timeline for advancing this experimental technology from laboratory tests to potential regulatory approval and commercialization.
Checked
12 claims in this story checked against 1 source: 11 supported.
Show each claim
- SupportedExtracts from experimental chewing gum reduced HPV levels by up to 93% in lab tests.Latest Science News -- ScienceDaily: “In laboratory tests using samples from cancer patients, researchers found that extracts from the gum reduced levels of human papillomavirus, or HPV, by as much as 93%.”
- SupportedAn enhanced version of the gum extract nearly eliminated two bacteria species associated with head and neck cancer.Latest Science News -- ScienceDaily: “An enhanced version also nearly eliminated two harmful bacterial species while leaving beneficial bacteria unharmed.”
- SupportedThe tested samples came from patients with head and neck cancer, and the results were from laboratory tests.Latest Science News -- ScienceDaily: “To investigate its potential benefits, the scientists tested extracts from the gum against microbes found in oral samples collected from patients with head and neck cancer.”
- SupportedThe study's quote from Daniell says the findings support advancing the therapies to clinical trials as adjuvants or prophylaxis.Latest Science News -- ScienceDaily: “Our findings support the value of advancing these therapies to clinical trials as adjuvants with current treatments or as prophylaxis to prevent infection and transmission.”
- SupportedThe research was led by Henry Daniell of Penn Dental Medicine and reported in Scientific Reports.Latest Science News -- ScienceDaily: “The research was led by Henry Daniell of the University of Pennsylvania's School of Dental Medicine.”
- SupportedThe bean-gum extracts lowered HPV levels by 93% in saliva samples and 80% in oral rinse samples.Latest Science News -- ScienceDaily: “The bean gum extracts lowered HPV levels by 93% in saliva samples and by 80% in oral rinse samples.”
- SupportedA single dose of the enhanced extract containing protegrin reduced the two targeted bacteria to almost undetectable levels.Latest Science News -- ScienceDaily: “With this additional ingredient, the researchers found that a single dose of the engineered gum extract reduced the two targeted bacterial species, Pg and Fn, to almost undetectable levels.”
- SupportedThe gum contains FRIL, a naturally occurring protein with antiviral properties, and can be engineered to include protegrin, an antimicrobial peptide.Latest Science News -- ScienceDaily: “This gum contains FRIL, a naturally occurring protein with antiviral properties. The team then took the technology a step further by engineering the gum to contain protegrin, an antimicrobial peptide.”
- Partly supportedThe antimicrobial peptide itself attacks harmful microorganisms while leaving the examined beneficial bacterial populations unaffected.Latest Science News -- ScienceDaily: “In contrast, the experimental gum extract sharply reduced the targeted bacteria without affecting the beneficial bacterial populations examined by the researchers.”
- SupportedDaniell said recently approved cancer medications have generally failed to produce major improvements in quality of life or five-year survival chances.Latest Science News -- ScienceDaily: “According to Daniell, recently approved cancer medications have generally failed to produce major improvements in patients' quality of life or their chances of surviving five years after diagnosis.”
- SupportedThe researchers' results came from laboratory testing of patient samples, not human clinical trials.Latest Science News -- ScienceDaily: “Importantly, the results came from laboratory testing of patient samples rather than clinical trials in which people chewed the gum.”
- SupportedThe researchers believe the findings justify moving the technology toward human clinical trials.Latest Science News -- ScienceDaily: “The researchers believe their findings justify moving the technology toward human clinical trials”